All three qualified biomarkers are enrichment biomarkers for clinical trials with BMS-708163, or avagacestat: an amyloid precursor protein secretase (γ-secretase) inhibitor that was developed by Bristol-Myers Squibb for the treatment of predementia and mild-to-moderate AD. The gene discussed is CTSB; the disease is Alzheimer disease.